Breaking News Instant updates and real-time market news.

APYX

Apyx Medical

$7.23

0.25 (3.58%)

16:30
11/11/19
11/11
16:30
11/11/19
16:30

Apyx Medical raises FY19 revenue view to $27.4M-$27.9M from $26.5M-$27.5M

Consensus $26.97M. Sees FY19 adjusted EBITDA ($16.9M)-($16.4M).

  • 11

    Nov

  • 12

    Nov

APYX Apyx Medical
$7.23

0.25 (3.58%)

03/14/19
PIPR
03/14/19
NO CHANGE
Target $10
PIPR
Overweight
Apyx Medical posted another solid quarter, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien says Apyx Medical posted another solid quarter in-line with its preannouncement, highlighted by "strong advanced energy growth off a tough comp." While the company's expense guidance may make the earnings outlook a little less favorable in the near-term, given the light penetration into this $1.5B market and the potential for several international expansions in 2019, its growth "should remain healthy for many years," O'Brien tells investors in a research note. He encourages risk tolerant investors to own the name and reiterates an Overweight rating on Apyx Medical with a $10 price target.
04/02/19
PIPR
04/02/19
NO CHANGE
Target $10
PIPR
Overweight
Piper continues to believe Apyx Medical will receive 510k clearance
Apyx Medical's decision to withdraw its 510k submission for dermal resurfacing following FDA pushback on various aspects of their study removes a source of upside and will "no doubt give legs to some of the theories floated in the short report," Piper Jaffray analyst Matt O'Brien tells investors in a research note. However, the analyst continues to believe that once Apyx "irons out" some of its clinical hurdles, the company will receive this clearance. Additionally, O'Brien feels that the product's use off-label for these procedures is likely reflective of J-Plasma's "unique utility in these situations," which allows him to remain constructive on the stock. He reiterates an Overweight rating on Apyx Medical with a $10 price target.
04/02/19
JMPS
04/02/19
NO CHANGE
Target $8
JMPS
Outperform
Apyx Medical price target lowered to $8 from $12 at JMP Securities
JMP Securities analyst David Turkaly lowered his price target on Apyx Medical shares to $8 from $12 after the company said it will voluntarily withdraw its 510(k) application for the use of its Renuvion product in dermal resurfacing procedures. Despite his belief that negative investor sentiment could be priced into the stock in the near-term, Turkaly said Apyx is still a significant grower and he still expects over 50% revenue growth in both 2019 and 2020, leading him to keep an Outperform rating on the shares.
05/08/19
PIPR
05/08/19
NO CHANGE
Target $7
PIPR
Overweight
Apyx Medical price target lowered to $7 from $10 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien lowered his price target on Apyx Medical to $7 after its Q1 results, adjusting his model after the company indicated that its pursuit of a dermal resurfacing indication with the FDA would be outside of the 2019 timeline. The analyst keeps his Overweight rating however and expects Apyx Medical's growth to remain healthy thanks to its "international expansion and core utilization in the US."

TODAY'S FREE FLY STORIES

COO

Cooper Companies

$313.10

1 (0.32%)

05:47
12/06/19
12/06
05:47
12/06/19
05:47
Recommendations
Cooper Companies analyst commentary  »

Cooper Companies should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

CRWD

Crowdstrike

$53.00

-2.04 (-3.71%)

05:45
12/06/19
12/06
05:45
12/06/19
05:45
Recommendations
Crowdstrike analyst commentary  »

Crowdstrike price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

FRPT

Freshpet

$57.40

2.57 (4.69%)

05:43
12/06/19
12/06
05:43
12/06/19
05:43
Recommendations
Freshpet analyst commentary  »

Freshpet price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHVN

Biohaven Pharmaceutical

$53.79

-0.235 (-0.44%)

05:42
12/06/19
12/06
05:42
12/06/19
05:42
Recommendations
Biohaven Pharmaceutical analyst commentary  »

Biohaven should be owned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQUA

Evoqua Water

$19.02

-0.09 (-0.47%)

05:31
12/06/19
12/06
05:31
12/06/19
05:31
Downgrade
Evoqua Water rating change  »

Evoqua Water downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MHK

Mohawk

$138.19

3.26 (2.42%)

05:29
12/06/19
12/06
05:29
12/06/19
05:29
Initiation
Mohawk initiated  »

Mohawk initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AOS

A.O. Smith

$46.89

0.53 (1.14%)

05:28
12/06/19
12/06
05:28
12/06/19
05:28
Initiation
A.O. Smith initiated  »

A.O. Smith initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEG

Leggett & Platt

$52.16

0.33 (0.64%)

05:27
12/06/19
12/06
05:27
12/06/19
05:27
Initiation
Leggett & Platt initiated  »

Leggett & Platt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OC

Owens Corning

$66.07

0.69 (1.06%)

05:26
12/06/19
12/06
05:26
12/06/19
05:26
Initiation
Owens Corning initiated  »

Owens Corning initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JELD

Jeld-Wen

$23.15

0.47 (2.07%)

05:25
12/06/19
12/06
05:25
12/06/19
05:25
Initiation
Jeld-Wen initiated  »

Jeld-Wen initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAS

Masco

$46.01

0.445 (0.98%)

05:23
12/06/19
12/06
05:23
12/06/19
05:23
Initiation
Masco initiated  »

Masco initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBP

Installed Building Products

$71.67

1.12 (1.59%)

05:22
12/06/19
12/06
05:22
12/06/19
05:22
Initiation
Installed Building Products initiated  »

Installed Building…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBHS

Fortune Brands

$63.90

0.74 (1.17%)

05:22
12/06/19
12/06
05:22
12/06/19
05:22
Initiation
Fortune Brands initiated  »

Fortune Brands initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WHR

Whirlpool

$144.83

2.825 (1.99%)

05:20
12/06/19
12/06
05:20
12/06/19
05:20
Initiation
Whirlpool initiated  »

Whirlpool initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

AWI

Armstrong World

$93.35

-0.87 (-0.92%)

05:19
12/06/19
12/06
05:19
12/06/19
05:19
Initiation
Armstrong World initiated  »

Armstrong World initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIEN

Ciena

$36.30

-0.3 (-0.82%)

, FB

Facebook

$199.35

0.65 (0.33%)

05:17
12/06/19
12/06
05:17
12/06/19
05:17
Downgrade
Ciena, Facebook, AT&T rating change  »

Ciena downgraded to Sell…

CIEN

Ciena

$36.30

-0.3 (-0.82%)

FB

Facebook

$199.35

0.65 (0.33%)

T

AT&T

$38.21

0.07 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 12

    Dec

  • 29

    Jan

RDY

Dr. Reddy's

$40.11

-0.03 (-0.07%)

05:15
12/06/19
12/06
05:15
12/06/19
05:15
Hot Stocks
Dr. Reddy's announces launch of Deferasirox Film-Coated Tablets in U.S. market »

Dr. Reddy's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOL

Toll Brothers

$40.90

0.79 (1.97%)

05:14
12/06/19
12/06
05:14
12/06/19
05:14
Initiation
Toll Brothers initiated  »

Toll Brothers initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

PHM

PulteGroup

$40.19

0.79 (2.01%)

05:13
12/06/19
12/06
05:13
12/06/19
05:13
Initiation
PulteGroup initiated  »

PulteGroup initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTH

Meritage Homes

$67.01

0.755 (1.14%)

05:12
12/06/19
12/06
05:12
12/06/19
05:12
Initiation
Meritage Homes initiated  »

Meritage Homes initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEN

Lennar

$59.82

0.96 (1.63%)

05:11
12/06/19
12/06
05:11
12/06/19
05:11
Initiation
Lennar initiated  »

Lennar initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBH

KB Home

$35.11

0.575 (1.67%)

05:10
12/06/19
12/06
05:10
12/06/19
05:10
Initiation
KB Home initiated  »

KB Home initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHI

D.R. Horton

$55.73

0.38 (0.69%)

05:09
12/06/19
12/06
05:09
12/06/19
05:09
Initiation
D.R. Horton initiated  »

D.R. Horton initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUM

Summit Materials

$23.60

-0.48 (-1.99%)

05:06
12/06/19
12/06
05:06
12/06/19
05:06
Downgrade
Summit Materials rating change  »

Summit Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGTA

Magenta Therapeutics

$12.99

-0.14 (-1.07%)

05:03
12/06/19
12/06
05:03
12/06/19
05:03
Initiation
Magenta Therapeutics initiated  »

Magenta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.